Pharma BD Deal Intelligence
Seven years and an upfront $91M later, CSL shut down the entire Calimmune-derived R&D site with no approved product and a terminated Phase I trial.
Full analysis, sources & comparables →CSL Behring paid $91M upfront for early-stage gene therapy assets, marking the plasma giant's deepest move into ex vivo HSC gene therapy.
CSL Behring is buying Calimmune for an early-stage stem cell and gene therapy boost, adding CAL-H plus the Select+ and Cytegrity manufacturing platforms aimed…
CSL Behring is shutting its Pasadena cell-and-gene therapy R&D site as part of a broader pivot away from ex vivo lentiviral vector gene therapy, affecting…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
CSL Behring agreed to acquire Calimmune for $91M upfront plus up to $325M in performance-based milestones over ~8+ years (~$416M total). The deal added the preclinical CAL-H stem cell gene therapy for sickle cell disease/beta-thalassemia plus Calimmune's Select+ enrichment and Cytegrity manufacturing platform technologies. CSL later refocused away from lentiviral gene therapy.
Seven years and an upfront $91M later, CSL shut down the entire Calimmune-derived R&D site with no approved product and a terminated Phase I trial.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| CSL Behring (CSL Limited) / Calimmune, Inc. (this deal) | 2017 | $416M | 15 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Otsuka Pharmaceutical Co. Ltd. / Astex Pharmaceuticals | 2013 | $886M | 79 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
← Browse all deals · How we score deals
More: 2017 deals · Hematology deals